{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:09:50Z","timestamp":1789132190727,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["NIH K12 DA041449"],"award-info":[{"award-number":["NIH K12 DA041449"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["NIH K12 DA041449"],"award-info":[{"award-number":["NIH K12 DA041449"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["NIH K12 DA041449"],"award-info":[{"award-number":["NIH K12 DA041449"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["NIH K12 DA041449"],"award-info":[{"award-number":["NIH K12 DA041449"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007268","name":"Washington University in St. Louis","doi-asserted-by":"publisher","award":["CADRA Grant"],"award-info":[{"award-number":["CADRA Grant"]}],"id":[{"id":"10.13039\/100007268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007268","name":"Washington University in St. Louis","doi-asserted-by":"publisher","award":["CADRA Grant"],"award-info":[{"award-number":["CADRA Grant"]}],"id":[{"id":"10.13039\/100007268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007268","name":"Washington University in St. Louis","doi-asserted-by":"publisher","award":["CADRA Grant"],"award-info":[{"award-number":["CADRA Grant"]}],"id":[{"id":"10.13039\/100007268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007268","name":"Washington University in St. Louis","doi-asserted-by":"publisher","award":["CADRA Grant"],"award-info":[{"award-number":["CADRA Grant"]}],"id":[{"id":"10.13039\/100007268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The postpartum period provides an opportunity for birthing people with opioid use disorder (OUD) to consider their future reproductive health goals. However, the relationship between the use of medication for opioid use disorder (MOUD) and contraception utilization is not well understood. We used multistate administrative claims data to compare contraception utilization rates among postpartum people with OUD initiating buprenorphine (BUP) versus no medication (psychosocial services receipt without MOUD (PSY)) in the United States (US).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this retrospective cohort study, we analyzed data from the Merative\u2122 MarketScan<jats:sup>\u00ae<\/jats:sup> Multi-State Medicaid Databases 2016\u20132021 among postpartum women with OUD who did and did not initiate BUP during pregnancy. Our primary outcome was the receipt of prescribed highly-effective or effective contraception by 90 days postpartum. Highly-effective contraception was defined as female sterilization and long-acting reversible contraception [LARC]). Effective contraception was defined as oral contraceptive pills [OCPs], the contraceptive patch, ring, or injection. We used multivariable Poisson regression models, adjusting for sociodemographic and clinical characteristics, to measure the association of BUP (vs. PSY) on postpartum contraception utilization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our sample consisted of 11,118 postpartum people with OUD. Among those, 3,443 initiated BUP and 7,675 received PSY. By 90 days postpartum, 22.4% (<jats:italic>n<\/jats:italic>\u2009=\u20092,487) of the cohort were prescribed contraception (21.5% PSY vs. 24.3% BUP). Among these participants, most received LARC (41.0%), followed by female sterilization (27.3%), the contraceptive injection (17.3%), pills (8.6%), ring (4.7%), and patch (1.0%), Compared to people engaged in PSY, BUP receipt was associated with a greater use of prescribed contraceptive use by 90 days postpartum (adjusted relative risk [aRR]\u2009=\u20091.17[1.07\u20131.28]), including a modestly greater use of the patch, ring, and pills, (aRR\u2009=\u20091.13[1.08\u20131.18]), but a modestly lesser use of injection contraception  (aRR\u2009=\u20090.95[0.91\u20130.99]). There was no relationship observed between BUP and LARC use (aRR\u2009=\u20091.00[0.95\u20131.04]) and female sterilization (aRR\u2009=\u20091.01[0.98\u20131.06]).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Only 22% of pregnant people with OUD in our cohort used effective or highly-effective postpartum contraception. BUP receipt during pregnancy, relative to PSY, was associated with modestly greater use of prescribed effective contraceptive methods but was not associated with greater use of provider-administered contraceptive methods, such as the contraceptive injection, LARC and female sterilization.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-024-00530-1","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T08:59:28Z","timestamp":1736153968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Buprenorphine and postpartum contraception utilization among people with opioid use disorder: a multi-state analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Kevin Y.","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Buss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendr\u00e9e E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Bierut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Stwalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah S.","family":"Szlyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin E.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie C.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony B.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E.","family":"Krans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Grucza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"issue":"1","key":"530_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.contraception.2018.08.008","volume":"99","author":"A Kotha","year":"2019","unstructured":"Kotha A, Chen BA, Lewis L, Dunn S, Himes KP, Krans EE. Prenatal intent and postpartum receipt of long-acting reversible contraception among women receiving medication-assisted treatment for opioid use disorder. Contraception. 2019;99(1):36\u201341.","journal-title":"Contraception"},{"key":"530_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.drugalcdep.2017.12.023","volume":"185","author":"EE Krans","year":"2018","unstructured":"Krans EE, Kim JY, James AE, Kelley DK, Jarlenski M. Postpartum contraceptive use and interpregnancy interval among women with opioid use disorder. Drug Alcohol Depen. 2018;185:207\u201313.","journal-title":"Drug Alcohol Depen"},{"key":"530_CR3","doi-asserted-by":"publisher","first-page":"100248","DOI":"10.1016\/j.dadr.2024.100248","volume":"12","author":"JK Bello","year":"2024","unstructured":"Bello JK, Xu KY, Salas J, Kelly J, Grucza RA. Contraceptive uptake in postpartum people with and without opioid use disorder and opioid use with co-occurring substance use. Drug Alcohol Depend Rep. 2024;12:100248.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"1","key":"530_CR4","doi-asserted-by":"publisher","first-page":"e2145175","DOI":"10.1001\/jamanetworkopen.2021.45175","volume":"5","author":"MI Rodriguez","year":"2022","unstructured":"Rodriguez MI, Meath T, Watson K, Daly A, Tracy K, McConnell KJ. Postpartum Contraceptive Use among US Medicaid recipients. Jama Netw Open. 2022;5(1):e2145175.","journal-title":"Jama Netw Open"},{"key":"530_CR5","unstructured":"ACOG. ACOG Committee Opinion 711. Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017."},{"issue":"2","key":"530_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/AOG.0000000000004659","volume":"139","author":"American College of O, Gynecologists\u2019 Committee on Health Care for Underserved Women CEEWG, Committee on E","year":"2022","unstructured":"American College of O, Gynecologists\u2019 Committee on Health Care for Underserved Women CEEWG, Committee on E. Patient-centered contraceptive counseling: ACOG Committee Statement Number 1. Obstet Gynecol. 2022;139(2):350\u20133.","journal-title":"Obstet Gynecol"},{"key":"530_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jsat.2018.12.001","volume":"98","author":"KW Collier","year":"2019","unstructured":"Collier KW, MacAfee LK, Kenny BM, Meyer MC. Does co-location of medication assisted treatment and prenatal care for women with opioid use disorder increase pregnancy planning, length of interpregnancy interval, and postpartum contraceptive uptake? J Subst Abuse Treat. 2019;98:73\u20137.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"530_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/sj.jp.7200357","volume":"20","author":"PJ Sweeney","year":"2000","unstructured":"Sweeney PJ, Schwartz RM, Mattis NG, Vohr B. The effect of integrating substance abuse treatment with prenatal care on birth outcome. J Perinatol. 2000;20(4):219\u201324.","journal-title":"J Perinatol"},{"issue":"8","key":"530_CR9","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1177\/0890117120927327","volume":"34","author":"EA Hurley","year":"2020","unstructured":"Hurley EA, Duello A, Finocchario-Kessler S, Goggin K, Stancil S, Winograd RP, et al. Expanding Contraception Access for Women with opioid-use disorder: a qualitative study of opportunities and challenges. Am J Health Promot. 2020;34(8):909\u201318.","journal-title":"Am J Health Promot"},{"key":"530_CR10","doi-asserted-by":"crossref","unstructured":"Stoltman JJK, Lander LR, Patrick JH, Terplan M, Jones HE. Interest in Co-located Reproductive and Sexual Health Services among women and men receiving medication for opioid Use Disorder in an Outpatient Treatment Clinic. Front Psychiatry. 2022;13.","DOI":"10.3389\/fpsyt.2022.910389"},{"key":"530_CR11","doi-asserted-by":"crossref","unstructured":"Shelton D, Ramage M, Hughes P, Tak C. Factors associated with contraceptive use among postpartum women with substance use disorder. Sex Reprod Healthc. 2022;33.","DOI":"10.1016\/j.srhc.2022.100764"},{"issue":"4","key":"530_CR12","first-page":"845","volume":"141","author":"KY Xu","year":"2023","unstructured":"Xu KY, Jones HE, Schiff DM, Martin CE, Kelly JC, Carter EB, et al. Initiation and treatment discontinuation of medications for opioid use disorder in pregnant people compared with nonpregnant people. Obstet Gynecol. 2023;141(4):845\u201353.","journal-title":"Obstet Gynecol"},{"issue":"16","key":"530_CR13","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1007\/s11606-023-08306-0","volume":"38","author":"KY Xu","year":"2023","unstructured":"Xu KY, Schiff DM, Jones HE, Martin CE, Kelly JC, Bierut LJ, et al. Racial and ethnic inequities in Buprenorphine and methadone utilization among Reproductive-Age Women with Opioid Use Disorder: an analysis of multi-state Medicaid Claims in the USA. J Gen Intern Med. 2023;38(16):3499\u2013508.","journal-title":"J Gen Intern Med"},{"key":"530_CR14","doi-asserted-by":"crossref","unstructured":"Lagisetty P, Garpestad C, Larkin A, Macleod C, Antoku D, Slat S et al. Identifying individuals with opioid use disorder: validity of International classification of diseases diagnostic codes for opioid use, dependence and abuse. Drug Alcohol Depen. 2021;221.","DOI":"10.1016\/j.drugalcdep.2021.108583"},{"issue":"5","key":"530_CR15","doi-asserted-by":"publisher","first-page":"e2211363","DOI":"10.1001\/jamanetworkopen.2022.11363","volume":"5","author":"KY Xu","year":"2022","unstructured":"Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA. Comparative effectiveness Associated with Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use. Jama Netw Open. 2022;5(5):e2211363.","journal-title":"Jama Netw Open"},{"issue":"7","key":"530_CR16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1176\/appi.ajp.2020.20081174","volume":"178","author":"KY Xu","year":"2021","unstructured":"Xu KY, Borodovsky JT, Presnall N, Mintz CM, Hartz SM, Bierut LJ, et al. Association between Benzodiazepine or Z-Drug prescriptions and Drug-related poisonings among patients receiving buprenorphine maintenance: a case-crossover analysis. Am J Psychiat. 2021;178(7):651\u20139.","journal-title":"Am J Psychiat"},{"key":"530_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.drugalcdep.2018.12.005","volume":"195","author":"L Clemans-Cope","year":"2019","unstructured":"Clemans-Cope L, Lynch V, Howell E, Hill I, Holla N, Morgan J, et al. Pregnant women with opioid use disorder and their infants in three state Medicaid programs in 2013\u20132016. Drug Alcohol Depen. 2019;195:156\u201363.","journal-title":"Drug Alcohol Depen"},{"issue":"5","key":"530_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/pds.3407","volume":"22","author":"Q Li","year":"2013","unstructured":"Li Q, Andrade SE, Cooper WO, Davis RL, Dublin S, Hammad TA, et al. Validation of an algorithm to estimate gestational age in electronic health plan databases. Pharmacoepidem Dr S. 2013;22(5):524\u201332.","journal-title":"Pharmacoepidem Dr S"},{"issue":"4","key":"530_CR19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s10995-015-1878-8","volume":"20","author":"SE Andrade","year":"2016","unstructured":"Andrade SE, Toh S, Houstoun M, Mott K, Pitts M, Kieswetter C, et al. Surveillance of medication use during pregnancy in the Mini-sentinel Program. Matern Child Hlth J. 2016;20(4):895\u2013903.","journal-title":"Matern Child Hlth J"},{"issue":"2","key":"530_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/0081175020982632","volume":"51","author":"SS Johfre","year":"2021","unstructured":"Johfre SS, Freese J. Reconsidering the reference category. Sociol Methodol. 2021;51(2):253\u201369.","journal-title":"Sociol Methodol"},{"key":"530_CR21","unstructured":"Corallo B, Tolbert J, Saunders H, Frederiksen B. Medicaid enrollment patterns during the Postpartum Year. Kaiser Family Foundation; 2022."},{"issue":"5","key":"530_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.contraception.2011.01.021","volume":"83","author":"J Trussell","year":"2011","unstructured":"Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397\u2013404.","journal-title":"Contraception"},{"key":"530_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1471-2288-14-82","volume":"14","author":"W Chen","year":"2014","unstructured":"Chen W, Shi J, Qian L, Azen SP. Comparison of robustness to outliers between robust poisson models and log-binomial models when estimating relative risks for common binary outcomes: a simulation study. Bmc Med Res Methodol. 2014;14:82.","journal-title":"Bmc Med Res Methodol"},{"issue":"2","key":"530_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.contraception.2012.11.009","volume":"88","author":"JB Perritt","year":"2013","unstructured":"Perritt JB, Burke A, Jamshidli R, Wang JX, Fox M. Contraception counseling, pregnancy intention and contraception use in women with medical problems: an analysis of data from the Maryland pregnancy risk Assessment Monitoring System (PRAMS). Contraception. 2013;88(2):263\u20138.","journal-title":"Contraception"},{"issue":"3","key":"530_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1176\/appi.ajp.2020.20020154","volume":"178","author":"LR McCloskey","year":"2021","unstructured":"McCloskey LR, Wisner KL, Cattan MK, Betcher HK, Stika CS, Kiley JW. Contraception for Women with Psychiatric disorders. Am J Psychiat. 2021;178(3):247\u201355.","journal-title":"Am J Psychiat"},{"key":"530_CR26","doi-asserted-by":"crossref","unstructured":"Rodriguez MI, Edelman AB, Skye M, Anderson L, Darney BG. Association of pharmacist prescription with dispensed duration of Hormonal Contraception. Jama Netw Open. 2020;3(5).","DOI":"10.1001\/jamanetworkopen.2020.5252"},{"issue":"2","key":"530_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.contraception.2020.10.012","volume":"103","author":"LM Eckhaus","year":"2021","unstructured":"Eckhaus LM, Ti AJ, Curtis KM, Stewart-Lynch AL, Whiteman MK. Patient and pharmacist perspectives on pharmacist-prescribed contraception: a systematic review. Contraception. 2021;103(2):66\u201374.","journal-title":"Contraception"},{"key":"530_CR28","unstructured":"Daniels K, Abma JC. Current contraceptive status among women aged 15\u201349: United States, 2017\u20132019. Hyattsville, MD: National Center for Health Statistics.; 2020. NCHS Data Brief, no 388."},{"issue":"1","key":"530_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.contraception.2017.10.003","volume":"97","author":"ML Kavanaugh","year":"2018","unstructured":"Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97(1):14\u201321.","journal-title":"Contraception"},{"key":"530_CR30","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1002\/jcph.1772","volume":"60","author":"RH Stone","year":"2020","unstructured":"Stone RH, Griffin B, Fusco RA, Vest K, Tran T, Gross S. Factors affecting Contraception Access and use in patients with opioid Use Disorder. J Clin Pharmacol. 2020;60:S63\u201373.","journal-title":"J Clin Pharmacol"},{"key":"530_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ypmed.2015.04.008","volume":"80","author":"M Terplan","year":"2015","unstructured":"Terplan M, Hand DJ, Hutchinson M, Salisbury-Afshar E, Heil SH. Contraceptive use and method choice among women with opioid and other substance use disorders: a systematic review. Prev Med. 2015;80:23\u201331.","journal-title":"Prev Med"},{"issue":"6","key":"530_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2307\/2135777","volume":"23","author":"KA Armstrong","year":"1991","unstructured":"Armstrong KA, Kenen R, Samost L. Barriers to Family-Planning-Services among patients in drug-treatment programs. Fam Plann Perspect. 1991;23(6):264\u201371.","journal-title":"Fam Plann Perspect"},{"issue":"1","key":"530_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/10826084.2019.1656255","volume":"55","author":"LK MacAfee","year":"2020","unstructured":"MacAfee LK, Harfmann RF, Cannon LM, Minadeo L, Kolenic G, Kusunoki Y, et al. Substance Use Treatment patient and provider perspectives on Accessing Sexual and Reproductive Health Services: barriers, facilitators, and the need for integration of Care. Subst Use Misuse. 2020;55(1):95\u2013107.","journal-title":"Subst Use Misuse"},{"key":"530_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.addbeh.2018.05.016","volume":"86","author":"EE Krans","year":"2018","unstructured":"Krans EE, Bobby S, England M, Gedekoh RH, Chang JC, Maguire B, et al. The pregnancy Recovery Center: a women-centered treatment program for pregnant and postpartum women with opioid use disorder. Addict Behav. 2018;86:124\u20139.","journal-title":"Addict Behav"},{"key":"530_CR35","doi-asserted-by":"publisher","first-page":"102111","DOI":"10.1016\/j.pmedr.2023.102111","volume":"32","author":"E Charron","year":"2023","unstructured":"Charron E, Kent-Marvick J, Gibson T, Taylor E, Bouwman K, Sani GM, et al. Barriers to and facilitators of hormonal and long-acting reversible contraception access and use in the US among reproductive-aged women who use opioids: a scoping review. Prev Med Rep. 2023;32:102111.","journal-title":"Prev Med Rep"},{"key":"530_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.socscimed.2018.02.013","volume":"201","author":"MR McLemore","year":"2018","unstructured":"McLemore MR, Altman MR, Cooper N, Williams S, Rand L, Franck L. Health care experiences of pregnant, birthing and postnatal women of color at risk for preterm birth. Soc Sci Med. 2018;201:127\u201335.","journal-title":"Soc Sci Med"},{"key":"530_CR37","doi-asserted-by":"publisher","first-page":"108634","DOI":"10.1016\/j.drugalcdep.2021.108634","volume":"221","author":"HE Jones","year":"2021","unstructured":"Jones HE, Martin CE, Andringa KR, Ellerson RM, Johnson E, Hairston E, et al. Sex and female empowerment (SAFE): a randomized trial comparing sexual health interventions for women in treatment for opioid use disorder. Drug Alcohol Depend. 2021;221:108634.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"530_CR38","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1007\/s11606-024-08689-8","volume":"39","author":"JK Bello","year":"2024","unstructured":"Bello JK, Xu KY, Salas J, Bedrick BS, Grucza RA. Pregnancy rates among women treated with medication for opioid Use Disorder. J Gen Intern Med. 2024;39(8):1342\u20138.","journal-title":"J Gen Intern Med"},{"key":"530_CR39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3102\/0091732X20903321","volume":"44","author":"S Viano","year":"2020","unstructured":"Viano S, Baker DJ. How administrative data Collection and Analysis can better reflect racial and ethnic identities. Rev Res Educ. 2020;44:301\u201331.","journal-title":"Rev Res Educ"}],"updated-by":[{"DOI":"10.1186\/s13722-025-00556-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000}}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00530-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-024-00530-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00530-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T15:10:23Z","timestamp":1741705823000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-024-00530-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["530"],"URL":"https:\/\/doi.org\/10.1186\/s13722-024-00530-1","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13722-025-00556-z","asserted-by":"object"}]},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13722-025-00556-z","URL":"https:\/\/doi.org\/10.1186\/s13722-025-00556-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dissemination to study participants and or patient organizations is not possible or applicable due to the de-identified nature of our data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Dissemination declaration"}},{"value":"Oral Presentation, AMERSA Annual Meeting, November 4 2023, Washington DC, USA","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Presentations"}},{"value":"Dr Grucza reported receiving grants from the NIH and Arnold Ventures LLC during the conduct of the study, consulting for Janssen Pharmaceuticals, and receiving personal fees for grant reviews from the NIH outside the submitted work. Dr. Krans is an investigator on grants to Magee-Women\u2019s Research Institute from the National Institutes of Health, Gilead, and Merck outside of the submitted work. These funding sources did not influence the design of the present study and the interpretation of data. The authors alone are responsible for the content and writing of this paper.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}